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CHAPTER 1
INTRODUCTION

A. A BRIEF HISTORY OF EPIGENETICS
The definition of epigenetics has varied in the past half century. Epigenetics was
once considered as a branch of biology that connected the two different fields of
development biology with genetics. In the 1940s, it was first introduced and described by
Conrad Waddington as the study of the interaction between genes and their products,
which influenced the phenotypic outcome (Waddington 1942). Waddington invented the
term ‘epigenetics’, which was derived from the Aristotelian word ‘epigenesis’ with “epi”
meaning “over” and ” genetics” referring to the genes involved in the epigenetic process.
He explained it as an event that is over or beyond the normal interaction of the
relationship between genes and phenotype. Waddington first developed the model of
canalization, which described a ball rolling down a hill into valleys that represented the
epigenetic landscape that was influenced by mutations in genes (Waddington 1953). The
influence of Waddington’s description has recently been revisited in new mathematical
models in modern studies of epigenetics to describe the stochastic noise associated with
altered chromatin landscapes that may underlie cellular plasticity and tumor cell
heterogeneity (Pujadas and Feinberg 2012)
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The classic historical view and definition of epigenetics has been transformed by
an emergence in a wealth of findings that have described multi-tiered layers of DNA
structural phenomena over the years. In 1975, Holliday and Pugh first introduced a new
meaning of epigenetics. Epigenetics was described as the study of the switching on and
off of genes during development (Holliday and Pugh 1975). It was proposed that
epigenetics is the process that influences the development of an organism without
alteration of the underlying DNA sequences themselves. Later on, Arthur Riggs
contributed to the idea by suggesting that there were heritable changes in gene expression
that pass through mitotic and/or meiotic cell divisions (Russo 1996) . These studies
combined the proposition that DNA methylation may regulate the switching on and off of
gene during development. Furthermore, DNA methylation was thought to be important
for the maintenance of these changes in gene expression through cell divisions (Reik and
Walter 2001). This gave a new connotation to epigenetics that has drawn much attention
to a vast number of growing research efforts in the epigenetics field related to cellular
differentiation, stem cell biology, human disease, and cancer. There are now many
epigenetic mechanisms that often function in a concerted manner to influence and
regulate gene expression patterns, while also retaining and preserving epigenetic
information between cell generations (Goldberg, Allis, and Bernstein 2007) (Reik 2007).

B. EPIGENETICS AND THE COMPLEXITY OF DNA STRUCTURE
In the study of epigenetics, the structure of the DNA molecule has essentially
taken on new characteristics. It can no longer be viewed simply as a double helical
structure containing only a naked base pair composition(Khorasanizadeh 2004). DNA is
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rather a complex of the basic DNA molecule with multiple proteins that function to
expand and contract the genetic material of the cell. The extent of this expansion ranges
from the complete unraveling of the DNA to permit the interaction and binding of
transcription factors that serve to activate transcription all the way to the ultra-condensed
contents of the chromosome required for cell division (figure 1.1).
At its most basic level of conformation, DNA can be best described in terms of its
association with core histone proteins in its more basic structure known as chromatin.
Chromatin as a unit is how DNA may be expanded and condensed during the cell cycle.
DNA within the chromatin is wrapped around core histone proteins organized into
octamers known as nucleosomes that take on a “beads on a string” appearance in
structure to form nucleosomes. A nucleosome is comprised of 147 bps of DNA wrapped
around an octamer of two copies of four core histones (H2A, H2B, H3 and H4) (Lunger
K 1997). The core histones contain a C-terminal domain and N-terminal tails that
protrude from the nucleosome and are subjected to different post-translastional
modifications. Histone tails are targets for a number of different enzymes that regulate
these post-translational modifications that include acetylation, phosphorylation,
ubiquitination and methylation (Wu J 2000). These combined alterations together form a
histone code or specific chromatin states that change the interaction of histones with the
DNA. The reorganization and restructuring of the chromatin conformation is associated
with regulation of gene expression connected with cellular processes(Cheung et al. 2000).
More specifically, specific alterations of key lysine residues within the histone tails serve
as regulatory targets that either repress or activate transcription(Allis et al. 2007).
Generally acetylation of most histones is associated with open and active conformation of
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chromatin that is catalyzed by a family of histone acetyltransferases(Kleff et al. 1995).
Methylation of histones can either repress or activate transcription based specifically on
which amino acids in the tail of histone are methylated. For example, addition of three
methyl groups to lysine 4 in H3 histone tail (H3K4Me) stimulate a transcriptional
activation while at lysine 9 in H3K9Me repress transcription (Grant 2001). Histone
methylation is coordinated by the histone methyltransferases (HMTs). Along with histone
methylation that is linked with transcriptional repression, histone deacetylation processed
by a variety of histone deacetylases (HDACs) is also a component involved in
transcriptional silencing, chromatin condensation, and heterochromatin assembly tethered
to events associated with cellular function and differentiation (Annunziato, Eason, and
Perry 1995).HDACs and HMTs are enzyme that influence the transcript by deacetylating
or acetylating the !-amino groups of lysine on histone proteins. Chromatin acetylation
links with transcriptional activity (euchromatin) which increases the gene expression, by
transferring acetyl group to lysine residues of N terminus of histone proteins which
reduces the affinity between histone and the DNA. This modification makes RNA
polymerase and transcripitions factor readily to access the promoter region.Whereas
deacetylation relates with gene silencing. Histone acetlyation is catalyzed by
acetyltransferases(HATs) and histone deactylases(HDs) that removes the actyl group
from !-amino groups of lysine on histone proteins which allows the histone protein to
wrap more tightly to the DNA which serves as the regulatory tagret which surpress the
transcripitional(Struhl 1998). Along with the modification of complexity of chromatin
structure, sometimes the DNA itslef would get methylated.
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Fig 1.1: Epigenetic modification: The environmental factors interacting with
epigenetic meachisms. This figure is modified from the original figure and
permission is granted for use in the thesis/ dissertation from Future Medicine,
(Alegria-Torres, Baccarelli, and Bollati 2011).

C. DNA METHYLATION
Beyond the complexity of modifications to the chromatin, the DNA itself can be
directly methylated at specific sites across the genome that is usually coordinated in
parallel with chromatin structural conformations. Methylation of DNA is most often
associated with transcriptional silencing, and is often co-localized with specific histone
modifications that reflect repressed chromatin. Highly methylated DNA is linked with
repression of transcription whereas unmethylated DNA is generally associated with
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transcriptional activation, with many exceptions to this generalization (Colot and
Rossignol 1999). DNA methylation generally takes place on the carbon 5 of cytosine,
most commonly within the context of cytosine phosphate guanine (CpG) dinucleotide
sequences. While DNA methylation takes place largely at CpG dinucleotides, the CpGs
themselves typically form clusters in select regions of the genome around gene promoter
or regulatory regions called CpG islands (CGIs)(Illingworth and Bird 2009), (Weinmann
et al. 2002) . CpGs that are found in intergenic regions are mostly methylated and
generally CpGs within the promoter regions are generally hypomethylated. Recent
studies have also revealed the importance of the sequences flanking CpG islands, called
CpG Shores, where CpG methylation is involved in tissue-specific cellular differentiation
tumorigenesis (RA Irizarry 2009). Thus, while CpG islands tends to serve regulatory
roles for many genes, including housekeeping genes, CpGs outside of CGIs may play a
more prominent role in differentiation and in epigenetic-related diseases (Weber et al.
2007). For example, DNA methylation is known to change with age in humans, and this
may play a role in age-related methylation occur in CpG shores or CpGs that are less
densely clustered and typically associated with chromatin structure that is indicative of
tissue-specific active chromatin (Day et al. 2013). Indeed the same tissue-specific
methylation changes associated with cellular differentiation largely overlap with the same
CpGs that differ between tumor and normal tissue samples, thus directly implicating
DNA methylation in promotion of tumorigenesis and the cancer stem cell hypothesis
(Feinberg, Cui, and Ohlsson 2002). More specifically in the case of cancer, large
stretches of CpGs known as differentially methylated regions or DMRs, may typically
lead to hypermethylation of tumor suppressor genes or hypomethylation of oncogenes
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leading to either the inactivation of tumor cell regulation or over expression of genes that
should rather be silenced (Reik 2001).
Methylation is controlled by the DNA methyltransferases (DNMTs), a family of
enzymes that catalyze the transfer of a methyl group from S-adenosyl methionine (SAM)
to the CpGs within the DNA. A family of DNMTs contains DNMT1, DNMT3a and
DNMT3b (Bestor 2000). The substrates of DNMT1 are hemimethylated CpGs that are
produced during S phase of the cell cycle when new DNA strands are synthesized (Shinichiro Takebayashi 2007). There is evidence that DNMT1 forms a complex by binding
with proliferating cell nuclear antigen (PCNA) via its PIP box and the transmission of the
methylation pattern to daughter cells (George-Lucian Moldovan 2007). For this reason,
DNMT1 has earned the name of the maintenance methyltransferase within the cell, and
provokes many questions as to the mechanisms of how methylation may change without
the context of DNA synthesis. More specifically, it has been found that some methylation
changes within subsets of neurons are rapid and in response to neurotransmitter within
the post-mitotic neuron in which methylation may mediate synaptic plasticity (C et al.
2013). This rapid changees in methylation state is thought to involve an intermediate
form of methylation known as hydroxymethylation (Guibert and Weber
2013).Hydroxymethylation is catalyzed by the ten eleven translocation (Kraus et al.)
hydoxylase family of enzymes that could play a role also in cellular differentiation by
marking regions of chromatin that are “poised” or prepared to reinitiate transcription
from a silenced site (Kinney and Pradhan 2013).In contrast with maintenance methylation
during cell divisions, DNA methylation patterns must also be first established during
embryogenesis after all parental methylation marks are essentially erased in the zygote
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(Hackett and Surani 2013).Later, after implantation, the embryo undergoes de novo
methylation that re-establish methylation pattern. New studies are reemphasizing how
epigenetic patterns may be inherited on a transgenerational manner which implicates
some level of epigenetic memory of the methylation pattern that was introduced by
parental gametes besides just imprinted genes that show parental specific methylation
patterns (Okano et al. 1999). While reestablishment of methylation patterns occurs in
embryogenesis, it is also taking place within the newly specified primordial germ cell
populations, but the mechanisms for how this is controlled are not well understood
(Seisenberger et al. 2013). Essentially, these de novo methylation events are involved
with embryonic specification and differentiation of early progenitor cell populations as
unique patterns are established. DNMT3a and DNMT3b are the de novo
methyltransferases that catalyze these early methylation patterns in the embryo (Chen et
al. 2005).

D. EPIGENETICS, ENVIRONMENT AND PHENOTYPE
As studies of complex human diseases expand beyond the analysis of genetic
variants,and as research uncovers the importance that epigenetic mechanisms play in
regulation of gene expression and in cell type determination, there is a rapidly growing
interest in how our environment influences our genes at the epigenetic level. Many
environmental factors such as dietary intake, exposure to chemicals, and even parental
care may indeed modify DNA structure through epigenetic mechanisms (Jaenisch and
Bird 2003).The important role of epigenetic variation on human phenotypic variations is
best supported by studies of epigenetic differences that arise during the lifetime of
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monozygotic twins (Singh, Murphy, and O'Reilly 2002).In one powerful initiating study,
there was a discordance that arose in total DNA methylation and histone methylation in
older monozygotic twins as compared to younger twins (Fraga et al. 2005). It is assumed
that older twins may exhibit more variations in epigenetic markers as a result of
differences in environmental exposure that may influence different outcomes of
phenotypes in twins when essentially their underlying DNA sequence is shared.
However, it still remains unknown what specific environmental influences impact the
epigenome. Animal models have also provided insights into the impact of epigenetic
modifications on phenotype. In particular, the yellow agouti (Avy ) mouse model has
directly demonstrated how epigenetic modifications (DNA hypermethylation at the
agouti locus) impact phenotype such as coat color (Morgan et al. 1999). Many studies of
environmentally induced epigenetic changes have now implicated factors such as
cigarette smoke, toxic chemicals, and or exposure to metals. A recent study showed
changes in DNA methylation patterns due to smoking, where there was a stronger
correlation between the offspring DNA methylation and paternal DNA methylation
patterns if parents and offspring both are non-smokers (p=0.02 and R2 corr = 0.41) and
the association completely disappeared if offspring were smokers(Hillemacher et al.
2008). Furthermore, it has been shown that the exposure to endocrine disruptor
vinclozolin (commonly used as a fungicide) stimulates epigenetic transgenerational
inheritance of disease in the mouse model. When mouse embryonic cells were exposed to
vinclozolin, abnormal male sexual differentiation and development was promoted, as
well as spermatogenic cell defects (Skinner, Manikkam, and Guerrero-Bosagna 2010)
(Anway et al. 2005). The cause behind this abnormality was demonstrated to be
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epigenetic reprogramming through DNA methylation of the male germ line. Therefore,
with exposure to a single environmental toxin like vinclozlin, a large scale epigenetic
effect was observed and further promulgates key questions as to how exposures to
multiple substances in our lifetime influences disease or our susceptibility to disease
compounded with our individual genetic background.

E. EPIGENETICS AND DIET
One such specific influence of environment on epigenetic modifications is our
diet. In particular, many studies have emphasized the influence of folate intake in the
diet. Folic acid is a source of the one carbon group necessary for DNA methylation. It
plays an important role in the metabolic pathway involving S-Adenosyl Methionine
(SAM), the methyl group donor in DNA methylation process (Razin and Shemer 1995).
Maternal folate deficiency during pregnancy showed DNA hypomethylation events due
to lower availability of SAM for DNA methylation (Scholl and Johnson 2000).The DNA
hypomethylation effected higher gene expression and also abnormal chromosomal rearrangements (Zaina, Lindholm, and Lund 2005). In a similar manner, case-control
studies demonstrated that alcohol consumption is associated with decreased expression of
tumor suppressor genes in colorectal cancer by epigenetics mechanism (Manon van
Engeland 2003).As mentioned previously regarding animal models an adverse
environment during fetal development was shown to influence phenotype in later life
induced by epigenetic changes. It was demonstrated that maternal diet altered the DNA
methylation of the agouti locus that caused phenotypic changes in coat color and body
weight (Waterland and Jirtle 2003). Many epidemiological type studies have also
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implicated diet in heritable epigenetic alterations. A study done on individuals prenatally
exposed to famine during the Dutch Hunger Winter (1944-1945) showed that coronary
heart disease and obesity rates changed amonf individuals, after exposure to famine in
early gestation compared to those not exposed to the famine (Painter, Roseboom, and
Bleker 2005). Later, Heijmans and colleagues proved that individuals prenatally exposed
to famine showed changes in methylation patterns in genes associated with growth and
metabolic diseases as compared with same-sex siblings who were not affected by famine
(Tobi et al. 2009),(El-Maarri et al. 2007). Many current studies continue to implicate the
influence of environment and diet on epigenetic processes in human populations that
could play strong roles in cancer, heart disease, and a variety of other diseases.

F. THE RELATIONSHIP BETWEEN DIET AND TRIGYLCERIDE LEVELS
Diet plays an important role in regulating triglyceride levels in the body.
Triglycerides (TG) are the main constituent of natural fats and oils. Triglycerides consist
of three molecules of fatty acid with a molecule of glycerol. In the metabolism of dietary
TGs, they are first broken down into free fatty acids and monoglycerides by pancreatic
lipase. These products are then absorbed by the small intestine where they are reformed
into TGs which packaged into chylomicrons that are secreted into the lymph system, and
eventually enter the blood stream. The chylomicron is then taken up by the liver and its
components are metabolized into the lipoproteins. A diet high in saturated fats and trans
fatty acids increase the TG levels in the body. Hyperglyceridemia is a condition where
the level of triglycerides is high (defined as TGs"150 mg/dL) and is one of the most
common disorders in the United States. It affects 30% of adults over the age of 20 years
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in the United States, and is more often found in males than females (Ford, Giles, and
Dietz 2002).The exact contribution of TG levels in coronary heart disease (CHD) risk has
been debated. However, the recent large-scale Prospective Cardiovascular Munster study
found hyperglyceridemia to be a contributor to CHD risk, particularly when HDLcholesterol concentrations are low (Cullen 2000) Studies have suggested that TG-rich
particles cause endothelial dysfunction and they may directly damage the endothelium
through an oxidative mechanism (Havel 2000).TG-rich particles have been shown to
cross the endothelial barrier and enter the arterial walls (Sattar, Petrie, and Jaap 1998).

G. TRIGLYCERIDES AND THE EPIGENOME
Recent studies have directly implicated TG levels as a function of diet in DNA
methylation. A population-based study was conducted that analyzed the influence of
dietary fat with levels of homocysteine concentrations, and they concluded that high
intake of saturated fatty acids are associated with elevated homocysteine concentration
(Berstad et al. 2007).Homocysteine is also a component of the methionine biosynthetic
pathway, which is responsible for generation of SAM as the source of methyl groups
required for DNA methylation. Therefore, alterations in homocysteine levels appear to
forms a link between the lipid metabolic pathways and DNA methylation pathways. One
component of recent study design is to test the response of TG levels as a result of fat
intake in the diet along with treatments to regulate TG levels by drugs. Fenofibrate is the
most common drug used to treat high TG and cholesterol levels in patients with
cardiovascular heart disease. Along with TG levels, Fenofibrate serves to lower the lowdensity lipoprotein cholesterol (LDL-C) while typically increasing high-density
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lipoprotein cholesterol (HDL-C). Fenofibrate treatment led to a 24-55% reduction in
plasma TGs concomitant with an 8-38% increase in HDL-C (Guay 2002).These effects
were mediated by activation of peroxisome proliferator-activated receptor-alpha
(PPAR#). PPAR# is a ligand-inducible transcription factor and a member of the nuclear
hormone receptor superfamily (Desvergne and Wahli 1999).Fenofibrate is a ligand that
binds and activates the PPAR#, which further modulates the expression of genes
regulating lipid metabolism (Willson et al. 2000).In recent studies using PPAR!-deficient
mice, homocysteine levels increased after fenofibrate treatment was completely
eliminated in these animals. It was concluded that fenofibrate may directly influence
homocysteine levels through a PPAR#-regulated mechanism [(Luc et al. 2004).

H. GOLDN STUDY
The Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study is one
of four networks in the National Heart, Lung and Blood Institute (Alencar et al.)
programs in Gene Environment Interaction (PROGENI). GOLDN is a multi-center
family study that was designed to identify genes with environmental interaction of the
response of lipids to two environmental conditions. The first condition is influence on
increase of TG levels (dietary fat) and the second context is the influence of
circumstances that lower TG levels (fenofibrate treatment). GOLDN had 184 pedigrees
(1,048 members, 3,500 relative pairs), and 860 members participated in a short-term (3
week) fenofibrate intervention, and then a high fat meal challenge was repeated in the
fenofibrate group. Personal history, medical history as well as dietary uptake were also
checked at each visit.
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I. EPIGENETIC STUDY OF THE GOLDN FAMILIES
The non-plasma component of whole blood from each blood draw (before and
after each intervention) was saved and frozen at -80°C. DNA was isolated from CD4+ T
cells from slowly thawed lymphocytes and DNA methylation at CpG sites was quantified
using the Illumina Infinium Human Methylation 450 assay across the genome. There
were a few reasons to specifically use the lymphocytes to study potential epigenetic
changes mediated by TG response. First, many key genes such as PPAR# that are
involved in lipid metabolism are expressed in lymphocytes (Bouwens, Afman, and
Muller 2008), so that their expression levels in these cell types may reflect the underlying
genetic and epigenetic variants that may be associated with TG response. Moreover, the
epigenetic modifications may be inherited through the germ line or early development
(Allegrucci et al. 2005).As a section of the GOLDYN consortium in the study of TGs and
DNA methylation changes, my study here has focused on collection of DNAs isolated
from CD4+ lymphocytes sorted from 995 individuals that had their blood drawn after
approximately a 12h fast (baseline) and at 3.5h (after participants drank a high fat shake).
This particular portion of the study as a whole is to determine baseline TG, genome-wide
methylation levels, and associated gene expression before any fenofibrate intervention.

J. CPT1A GENE
The anaylsis of the GOLDN epigeneticc data identified a key gene associated
with TG levels. Here I will introduce the function of this key enzyme as it relates to the
baseline fasting study here. The CPT1A gene encodes the carnitine
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palmitoyltransferase1A enzyme that is present on the outer mitochondrial membrane in
the liver. It is a key enzyme in the carnitine-dependent transport of long fatty acids into
the mitochondria. The long-chain fatty acids cannot penetrate the mitochondria
membrane if they are not attached to carnitine. Carnitine plays an important role in
transporting of long-chain fatty acids from the cytoplasm to the mitochondria matrix
(Longo, Amat di San Filippo, and Pasquali 2006). During the fasting period, long-chain
fatty acids serve as an important source of energy for liver and other tissues. The longchain fatty acids with lengths of 14 or more carbons need to undergo activation to enter
the mitochondria; this process is divided into three enzymatic reaction steps. First, fatty
acid is converted by acyl-CoA synthetases to give fatty acyl-CoA. Fatty acyl- CoA then
attaches to the hydroxyl group of carnitine to form fatty acyl-carnitine. CPT1A connects
the carnitine to fatty acids and facilitates the movement of fatty acid from outer member
to inner member space of mitochondria; the cartinitine is displaced then by an CoA group
to reform fatty-CoA in the mitochondria matrix where beta-oxidation of fatty acid takes
place as a source of energy (Fritz and Marquis 1965, Dobbins et al. 2001). Three tissuespecific CPT1 isoforms exist including the liver (CPT1A), muscle (CPT1B) and brain
(CPT1C) forms (Bonnefont et al. 2004). The deficiency in CPT1A leads to a disorder of
fatty acid oxidation. The patients show clinical symptoms like low levels of fatty acid
breakdown products (hypoketosis), low blood sugar (hypoglycemia), weakness, and
damage to liver, muscles or brain (Bennett and Santani 1993). Here, I report my findings
regarding the elucidation of methylation changes associated with TG levels and how
these changes ultimately appear to influence the gene expression of the CPT1A within
lymphocytes.
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CHAPTER 2
MATERIALS AND METHODS

A. BLOOD SAMPLE AND DATA COLLECTION
Specifically for this study, blood was drawn from 995 participants that were asked
to fast for "12 hours and abstain from alcohol intake for "24 hours. A second blood
sample for the same individuals was taken 3.5 hours later after the consumption of a
high-fat shake. Blood collected at first time point was used for isolation of DNA to
generate DNA methylation data, while buffy coat collected at the 3.5h time point was
used for RNA isolation. A number of different measurements were taken from
participants in collaboration with the University of Alabama at Birmingham (UAB)
Department of Epidemiology and with the Nutrition and Genomics Laboratory at the Jean
Mayer-USDA-Human Nutrition Research Center on Aging at Tufts University.
Approximately 10mL of drawn blood was lightly spun at 200xg to remove the white cell
layer to enrich samples for a buffy coat. The upper plasma layer was set aside for blood
lipid analysis. A small layer of plasma was left above and red blood cells below for each
buffy coat before freezing at -80°C ( figure 2.1 A). TGs were measured by a glycerolblanked enzymatic method (Trig/GB, Roche Diagnostics Corporation, Indianapolis, IN).
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TC was measured using a cholesterol esterase–cholesterol oxidase reaction (Chol R1,
Roche Diagnostics Corporation) on the Roche/Hitachi 911 Automatic Analyzer (Roche
Diagnostics Corporation). The same reaction was also used to measure HDL-C after
precipitation of non-HDL-C with magnesium/dextran. LDL-C was measured by a
homogeneous direct method (LDL Direct Liquid Select™ Cholesterol Reagent, Equal
Diagnostics, Exton, PA). Nuclear Magnetic Resonance (NMR) spectroscopy measured
very low-density lipoprotein cholesterol (VLDL-C) (Liposcience, Raleigh, NC). Data on
medical history, physical activity and other lifestyle factors such as alcohol intake,
smoking status and diet were collected using an interviewer-administered questionnaire.

B. CELL SORTING OF CD4+ T LYMPHOCYTES FROM BASELINE THAWED
BUFFY COATS
As described in the introduction, enrichment of CD4+ T lymphocytes was
advantageous for analysis of genome-wide methylation. In order to preserve cellular
structure from previously prepared frozen buffy coat samples, 4-5mL buffy coats
containing a small fraction of plasma and red blood cell layers were thawed very slowly
on ice for approximately 2h before cell sorting procedures. To test the feasibility of
enrichment procedures, both a fresh collected buffy coat sample and a thawed buffy coat
sample were immunolabeled with anti-CD3-AlexaFluor488 to label all T cell populations
within buffy coat samples. After washing with phosphate buffered saline (PBS)
containing 1% BSA and lightly pelleting immunolabeled cells and resuspending, an
aliquot of cells was removed for imaging under an Olympus BX41 polarizing microscope
with an Exfo Xcite series 120 light source and a CytoViva Dual Mode Fluorescence
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module. Images were captured through a Microfire camera attached through a condenser
mount using Microfire image software for Mac in partial fluorescence mode with an oil
immersion 40X lens to verify labeling of T cells from freshly collected buffy coat
sample. Resuspended cells were then mixed with anti-CD4 Dynabeads to sort CD4+ T
cells from the resuspended cell pellet. After capturing cells on a Dynal magnet (Life
Technologies), and washing with PBS, another sample of Dynabeads were collected for
imaging under the microscope to verify enrichment of CD3-labeled T cells attached to
Dynabeads. The fluorescent signal within T cell membranes was partially obscured by
clumping of Dynabeads that exhibited high autofluorescence that was difficult to prevent
during imaging because the Olympus BX41 polarizing microscope contained only a triple
pass filter that allows simultaneous image capture without being able to capture in each
color channel with separate filter systems.
Based on this initial labeling test, a protocol was developed for sorting of CD4+ T
cells from slowly thawed buffy coat samples. After blood is thawed, 300#l was removed
and stored in -30°C as buffy coat. In 15ml conical tubes, 3ml of buffer from Qiagen
DNeasy Blood & Tissue Kit and 75 #l of CD4+ Dynal beads from Dynabeads® CD4
Positive Isolation Kit (Invitrogen™) was added. Once beads were added to the 15ml
tubes, they were kept on ice for the rest of time shown in (figure 2.1 B) . Using a 10ml
serological pipet, the remainder buffy coat was removed and added to the 15ml tube
containing buffer 1 and CD4+ dynabeads and placed in a 15ml tube on the rotator for 2025 minute at 4°C. After removing from rotator, tubes were placed on 15ml Dynal
magnets and allowed to settle for 2 minutes.
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Plasma layer for blood lipid anaylsis
Buffy coat for DNA and RNA extraction
Red blood cells

Fig 2.1: A) GOLDN blood sample collection used for different analysis. Buffy
coat used for DNA and RNA extraction B) Isolation of CD4+ T cell. From thawed
buffy coat using Dynabead. Source:www.cromoion.com/content.php?id=218&cc=6.
!

Using a serological pipet, supernatant from tubes was carefully removed while
tube is on magent, supernatant was stored at -80°. Three ml of buffer 1 was added to a
tube which is on the magnet. A tube was removed from magnet for gently vortex and
again placed it back to the magnet to settle for a minute. Later wash was removed and
discarded and this step was repeated two more time to wash the Dynabeads. After wash
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step, a standard proteinase K protocol from Qiagen DNeasy kit was performed for DNA
extraction.

C. ILLUMINA HUMAN METHYLATION 450K ARRAYS
The Infinium Human Methylation450 Beadchip interrogates ~470,000 autosomal
CpG dinucleotide sites across the genome for up tio 12 bisulfite-cinverted genomic DNA
samples per array .Each CpG on the array has specific probes that detect both methylated
and unmethylated DNA at each CpG, and these CpG probe beadtypes are represented
multiple times across the array. During data processing, all of the different beadtypes are
accounted for and integrated to calculate the methylation level for each represented CpG.
In preparation for bisulfite conversion for arrays, samples were randomized into 96 well
plates across 84 total plates. 500ng of each DNA sample was treated with sodium
bisulfite according to standard protocol (Zymo EZ-96 DNA methylation kit,
ZymoResearch Inc., Irvine, CA). Bisulfite converted DNA (BCD) plates were then used
for whole genome scale amplification, hybridization to methylation450k arrays and then
final extension steps to incorporate single bases conjugated to red or green fluorophores.
Arrays are then protected with XC4 reagent before vacuum drying and imaging steps
using an Illumina iScan high precision microarray laser scanner. The resulting intensity
value files are imported into Illumina GenomeStudio software, which automatically
generates beta scores (calculated as the percent methylation by taking methylated probe
intensity values divided by the total intensity values of methylated plus unmethylated
plus 100). GenomeStudio also automatically flags both probe signals and samples that do
not meet certain quality thresholds. More specifically, fluorescent signals that fall below
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or within the range of overall background signal intensities (according to negative control
probes incorporated on the array) are given detection P-values that allow for confidence
in whether the total intensity for a given probe falls within the background signal
intensity. Beta scores that held associated detection P-values greater than 0.01 were
removed and samples with more than 1.5% missing data as measured by detection Pvalues were eliminated from further analysis. If the same probes yielded detection Pvalues above 0.01 across more than 10% of samples, these particular probes representing
single CpGs were removed from the analysis. A total of 58 samples were removed by
this quality filtering step to yield a total of 995 samples.
The filtered beta scores were then subjected to batch normalization with an
empirical Bayes framework method with non-parametric mode built into the ComBat
package for R software (Johnson, Li, and Rabinovic 2007). Batch normalization is
required because intensity values may slightly vary from array to array based on mild
technical differences in the array processing and scanning. Normalization was performed
in parallel across subsets of 20,000 CpGs to cover all CpGs across the array where each
array of 12 samples was considered a separate batch. This method has been extensively
described in previous papers published in the Absher Lab (Absher et al. 2013). In which
ComBat was compared to some other methods for batch correction using other programs.
In addition probes were also normalized separately according to their chemistry. There
are two types of chemistries known as Infinium I and Infinium II beadtypes that simply
refer to a one color or two color determination of beta scores, respectively. For
normalization probes from the Infinium I and II chemistries were subdivided the $ scores
for Infinium II probes were adjusted compared to Infinium I using an equation derived
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from fitting a second order polynomial to the observed methylation values across all pairs
of probes located <50bp apart (within-chemistry correlations > 0.99), where one probe
was Infinium I and one was Infinium II. Lastly, any CpGs where the probe sequence
actually mapped either to a location that did not match the annotation file, or to more than
one locus were also removed from the analysis. These mis-mapped CpGs were isolated
by re-alignment of all probe sequences (with unconverted Cs) to the human reference
genome. Following these quality control procedures, the final methylation data set
contained 461,281 CpGs.
Principal components (PCs) based on the beta scores of all autosomal CpGs that
passed quality control were calculated using the prcomp function in R software. Using
these PCs, methylation data could be corrected for variations in the purity of CD4+ Tcells with Dynabead cell sorting.The ability of PCs to correct for contamination of the
CD4+ T-cells was assessed using a developed method developed in the Absher Lab.
Deconvolution-estimated CD4+ T-cell percentages were calculated with adaptation of a
previously published method (Abbas et al. 2009), which estimates proportions of
component cell-types in a sample via linear regression. The enrichment of T cells
predicated using this method was highly correlated with PC1 (r2=0.85, P=4*10-293), but
not with other PCs. This result demonstrates the adjustment for principal components in
the lineat regression models used for association analysis is adequately accounting in
CD4+ T-cell enrichment between samples.
Linear mixed models, which accounted for the family-structure of the data via a
kinship matrix model correlation between relatives, were used to model beta scores for
CpGs as the model outcome.The independent variable of interest in these models was the

!

##!

!

log values of plasma TG levels with age, gender, blood collection site, and PC1-PC4
serving as other fixed effects covariates within the model.
A Bonferroni correction for multiple testing among the results using a p-value
cutoff of 1.8*10-7 (0.05/461, 281=1.8*10-7).The R function lmekin within the kinship
package was used to fit the linear mixed models. The lmekin function fits a linear mixed
effects model, which incorporates relatedness between individuals into covariance
structure of the random effects, while the fixed effects are used to test fot association and
adjust for potential confounders. Because environmental factors can directly confound
EWAS by affecting both the epigenotype and phenotype, sensitivity analysis adjusting
for potential major sources of confounding including current alcohol use and current
smoking use in models that produced significant findings was conducted. A second
sensitivity analysis considered additional sources of confounding including physical
activity, diet, and education (as a proxy for socioeconomic status). We have previously
described this population to be very genetically homogeneous and have not adjusted for
substructure.(Aslibekyan, Kabagambe, et al. 2012, Aslibekyan, An, et al. 2012,
Aslibekyan, Goodarzi, et al. 2012) However, principal components based on SNP data
from GWAS (SNP PCs) calculated in Eigenstrat (Aslibekyan, Kabagambe, et al. 2012)
were available for 72% of our study population and the first 10 SNP PCs were included
in the second sensitivity analysis described.
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D. TOTAL RNA ISOLATION AND REAL TIME RT-PCR
With approximately 5mL of buffy coat from the collection 3.5h following
administration of the high fat shake, various methods were attempted in order to deplete
samples of red blood cells from thawed buffy coats in order to prevent total RNA
samples from containing an excessive contribution of globin mRNAs. The QIAamp®
RNA blood mini kit ,MagaZorb® total RNA mini-prep kit commercially available total
RNA isolation kits did not yield RNA of acceptable quality for gene expression studies.
Total RNA isolation required the Trizol extraction method (Life Technologies). To
preserve total RNA sample integrity, frozen 5mL frozen buffy coats within 5mL capped
tubes, were uncapped and submerged in 50mL conical tubes containing 15mL of Trizol
solution, vortexed rigorously and refrozen in 5mL aliquots.
5mL of homogenized buffy coats were thawed and 3mL of chloroform was added
for phase separation. After dividing samples into 2mL microfuge tubes, samples were
spun at 4°C at 12,000xg and the aqueous phase was removed. Ethanol (1.5 fold volume)
was added to aqueous phases and total RNAs were isolated by RNeasy Mini kit (Qiagen).
RNA integrity was determined by Bioanalyzer with an RNA nano Kit (Agilent); all RNA
preparations using the Trizol extraction with RNeasy columns generated RIN values
between 8 and 10. Total RNA was quantified by Qubit RNA fluorometry (Life
Technologies). For synthesis of cDNA, 2ug of input RNA was used in a 40ul reaction
using an iScript cDNA synthesis kit (BioRad). Template cDNAs were diluted 1:4 and
relative mRNA expression levels were quantified in triplicate 10ul reactions by TaqMan
gene expression assays with a 7900HT Real Time PCR system according to standard
PCR cycling conditions (Applied Biosystems). All gene expression assays were
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purchased from Life Technologies: Hs00912671_m1 (CPT1A), Hs00912681_m1
(CPT1A), Hs00168719_m1 (PPIB), Hs00154728_m1 (DECR1), Hs02786624_g1
(GAPDH), Hs00984230_m1 (B2M), Hs00951083_m1 (TFRC), Hs00923579_m1 (HBZ).
ExpressionSuite v1.0.3 software was used for assessment of candidate endogenous
controls by comparison of expression stability scores. GAPDH yielded the highest
relative stability score (4.0) when compared to all endogenous controls and was discarded
from analysis. HBZ was used as an internal control for minor red blood cell contribution,
but was not used in the analysis because Ct values were relatively much higher than all
other genes. Ct (threshold cycle) is the intersection amplification curve and a
threshold line. The threshold cycle is inversely proportional to the original relative
expression level of the gene of interest.B2M was also discarded as a candidate
endogenous control as its relative Ct across samples was much lower than CPT1A targets
and remaining candidate endogenous controls, and held the highest relative stability score
(0.98) compared to scores for the final selected endogenous controls PPIB (0.61), the
protein encode by Peptidyl-prolyl cis-trans isomerase B gene related to secretory
pathway and released in biological fluids. This protein can bind to cells derived from Tand B-lymphocytes.Second endrogenous control was DECR1 (0.66) 2,4-Dienoyl CoA
Reductase 1, Mitochondrial is an auxiliary enzyme of beta-oxidation. It participates in the
metabolism of unsaturated fatty enoyl-CoA esters having double bonds in both even- and
odd-numbered positions., and last one was TFRC (0.82), Transferrin Receptor is
required for iron delivery from transferrin to cells (Stamova et al. 2009). ExpressionSuite
was also used to assess flagged reactions within triplicates and poor quality Ct values
were removed also after visual inspection of reaction curves for further verification.
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Reaction Ct values for the two CPT1A probes yielded nearly identical results and were
averaged. Individual Ct values for each endogenous control were median centered, and
the three selected endogenous control Ct values were averaged per sample and subtracted
from median centered CPT1A target Ct values to generate ddCt input for relative
quantitative method (2-ddCt). These relative fold CPT1A levels were used for further
analysis with methylation levels.

E. ASSESSMENT OF CPT1A GENE EXPRESSION WITH METHYLATION
LEVELS
Normalized CPT1A expression values were compared to the methylation level at
cg00574958 corrected for the first 4 methylation principal components using linear
regression with methylation beta-scores as the outcome variable. Since the expression
data was obtained from unrelated individuals, it was not necessary to account for family
strtucture via linear mixed models as was done for models of association between
methylation and triglyceride.
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CHAPTER 3
RESULTS

A. DYNABEAD-SORTED T LYMPHOCYTES FROM THAWED BUFFY COAT
SAMPLES
CD4+ T-cells are one of the most abundant lymphocyte populations in whole
blood. Based on our interest in assessing blood lipid levels and their potential influence
on DNA methylation, isolation of a single population of cells to analyze genome wide
changes was required. Previous work in the Absher Lab has shown that proportions of
blood cells are very dynamic, and the sensitivity of methylation data can detect both
methylation effects associated with disease states as well as changes in cell populations
(Absher et al. 2013). Therefore, by controlling for a single cell population in our TG level
association with methylation, this eliminates some of the variability in methylation levels
that may be connected with changes in cell proportions alone.
An anti-CD4 conjugated Dynabead cell sorting protocol was developed to enrich
for CD4+ T-cells from thawed buffy coat samples collected from individuals. Dynabeads
provide a simple and affordable alternative to fluorescence activated cell sorting (FACS).
FACS is typically used to specifically isolate multiple lymphocyte populations using a
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wide variety of antibodies toward many antigens specific to each cell type (Loken and
Herzenber 1975). Dynabeads also carried the advantage of bypassing the potential
harsher treatment of cells that are associated with FACS such as multiple incubation steps
with antibodies, wash steps, and the passing of cells through a laser beam. We assumed
that the vast majority of cells sorted from thawed buffy coats would mostly be composed
of non-viable cells because standard cryogenic procedures were not used to preserve
these samples such as the addition of DMSO and fetal calf serum. Furthermore, with
thawed cells there is enhanced clumping of cells through partially or fully ruptured
plasma membranes that would be extremely difficult to use for FACS procedures.
Therefore, we used Dynabeads as this would allow for maximized enrichment of
CD4+cells from thawed buffy coat samples. Dynabeads in general are uniform,
superparamagnetic beads that are 4.5 #m in diameter. The beads are then coated with a
primary monoclonal antibody specific for the CD4 membrane antigen that is expressed
on human T helper cells. Dynabead sorting also provides an advantage of isolation from
fairly viscous samples such as whole blood or buffy coat. Lastly, cells may also be lysed
directly while attached to the beads to isolate DNA.
We hypothesized that the partial plasma layer and red blood cell layers could
theoretically serves as a cryoprotectant. However, in order to demonstrate enrichment of
CD4+ T cells from thawed buffy coats, we performed an experiment to directly observe
T lymphocytes sorted with Dynabeads from both freshly prepared buffy coats and thawed
buffy coats in parallel. Frozen buffy coats were removed from -80°C onto ice for
approximately 2h to ensure a slow thaw for preservation of cellular structure and any
viable cells. We immunolabeled 200ul of both fresh and thawed buffy coat samples with
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both anti-CD3-AlexFluor488 (1:20) and 75µl of anti-CD4-Dynabeads for approximately
30 minutes at 4°C. A separate fraction of fresh buffy coat was immunolabeled with antiCD3 alone. The CD3 antigen is a pan-T cell molecule that is associated with activation of
T cells as it interacts with the T cell receptor. By co-labeling with anti-CD3, we were able
to detect fluorescently labeled cells associated with Dynabeads. After immunolabeling,
cells/beads were placed on a magnet and resuspended and washed three times in a PBS
buffer containing 1% BSA. We easily observed labeled cells in buffy coats directly
labeled with anti-CD3 alone (Figure 3.1A). When we sampled 10ul of Dynabead
enriched cells, we found that Dynabeads are extremely autofluorescent, and our
microscope did not permit filtering of fluorescent signal background. However, we were
able to easily detect green fluorescently labeled cells attached to Dynabeads from freshly
collected buffy coat samples (Figure 3.1B). Immunolabeled cells attached to Dynabeads
from thawed buffy coats were more difficult to detect because the fluorescent signal was
much weaker, but some cells were detected in spite of the strong neighboring
autofluorescent signal associated with the Dynabeads (Figure 3.1C). We did not test for
whether these apparently intact cells were indeed viable, as we assumed that these sorted
cells that held structure enough to be isolated with the Dynabead procedure.
Based on these results, we confirmed that it was possible to enrich for CD4+ T
cells for genomic DNA isolation, regardless of their viability. For isolation of DNA, the
viability of sorted cell populations was also not as critical as compared to isolation of
RNA that will be discussed later. Furthermore, even if isolated genomic DNA was
partially fragmented, the genomic DNA is fragmented for methylation arrays anyway as
these samples must also be bisulfite treated and amplified. Bisulfite conversion is a harsh
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procedure that typically fragments the DNA, and amplification of this material for
Illumina methylation450 arrays also fragments the DNA.
To isolate genomic DNA, we used the same Dynabead sorting procedures as
above, and lysed cells directly after enrichment on the magnet and used DNeasy
procedure. We tested for the enrichment of CD4+ T cells again from fresh, thawed, and
buffy coats without cell sorting by running methylation450 arrays on these samples along
with principal component analysis to cluster samples based upon their methylation
profiles. Principal component analysis calculates values that the depict variation
differences among samples that allows for assessment of how close the overall data
points generated for each sample compare to one another.
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Fig 3.1: Dynabead enrichment of CD4+ T lymphocytes from freshly isolated
and thawed buffy coat samples. A)Lymphocyte populations were directly
immunolabeled with anti-CD3-AlexaFluor488 and anti-CD4-Dynabeads. Labelled
cells were detected in non-enriched samples of freshly isolated buffy coat. B)
Double labeled, Dynabead enriched cells from freshly isolated compared to
thawed isolated, C) T cells showed association of beads with membrane
fluorescent signal. Arrowheads depict CD3+ T lymphocytes.
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Our results strongly suggested that extracted DNA from sorted cells isolated from
thawed buffy coat samples produced very similar methylation profiles to DNA extracted
from sorted cells isolated from fresh buffy coats (Figure 3.2) Furthermore, DNAs from
whole buffy coat samples that were not enriched for CD4+ cells clustered separately from
the CD4+ enriched population, and suggests that the Dynabead sorting procedure
enriched for DNA that could be isolated from CD4+ T cells from thawed buffy coat with
about the same consistency as fresh buffy coats. Therefore, these results provided
evidence that the Dynabead sorting procedure was reliable for isolation of T cells for
thawed buffy coat samples to be used on Methylation450 arrays.
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Fig 3.2: Principal component analysis of genome wide methylation
data generated using extracted DNA from freshly isolated buffy
coat. CD4+ T cells from freshly isolated buffy coat and thawed buffy
coats. Principal component 1 (x-axis) was plotted against principal
component 2 (y-axis). Black circles represent samples enriched for
CD4+ T cells isolated from thawed buffy coats, and red triangles
represent T cell enriched samples from fresh buffy coats. Blue squares
indicate whole fresh buffy coat samples. Red oval is drawn to
encompass all fresh sorted samples compared overall to all enriched
thawed samples. Blue oval encompasses all non-enriched fresh buff
coat samples.
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B. GENOME-WIDE METHYLATION ASSOCIATED WITH BLOOD LIPIDS
AND TRIGLYCERIDES IN GOLDN SAMPLES
As part of the GOLDN study consortium, DNA was extracted from Dynabeadsorted CD4+ T cells from thawed buffy coats of 995 participants. The average age of all
of the participants was 48.8±16 years, and approximately 52% were female. The total
numbers of blood samples were split even between the two different locations where the
blood was collected. To measure the potential relationship between epigenetic changes in
DNA methylation and blood lipid levels, various blood lipid measurements were
performed. Mean fasting lipid levels (±SD) were 190.0±38 for total cholesterol, 121.6±31
for LDL-C, 47.0±13 for HDL-C, 105.3±93 for VLDL-C, and 137.0±95 for TGs. The
mean levels across all of these samples were within the normal range according to ATP
III Guidelines (Talwalkar et al. 2013).
Using the genome-wide methylation profiles generated on methylation450 arrays,
we analyzed the association between specific methylation levels at select CpGs across the
human genome. A number of different CpGs significantly associated with blood lipid
levels were identified using linear mixed statistical models at each CpG. As shown in
both Figure 3.3 and Table 1.1, there were statistically significant CpGs associated with
VLDL-C and TGs. We found that two of the strongest CpGs were both associated with
VLDL-C and TGs levels (cg00574958 and cg17058475) out of approximately 460,000
total CpGs and were located within the carnitine palmitoyltransferase 1A (CPT1A) gene.
For TGs, P-values were P=5.3*10-14 and P = 1.2*10-7, respectively, and P = 6.8*10-11,
and P= 2.0*10-8 for VLDL-C. At this most significant CpG, a subset of unrelated
individuals were used to estimate the variance in the baseline (fasting) TG levels
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explained by CPT1A methylation. We found that approximately 2.4% of TG variance
could be explained by methylation at cg00574958. With closer examination of these
significant CpGs, they were both located in the first intron of the CPT1A gene 116bp
apart from one another at the genomic coordinates chr11:68607622 (cg00574958) and
chr11:68607738 (cg17058475) (figure 3.4). We also found that these 2 CpGs are
positioned between 2 different CpG islands and 2 different clusters of highly conserved
regions among mammals. Furthermore there is a putative enhancer region reported on the
leftmost conserved element that contains consensus PPARa binding sites according to a
previous study (Napal, Marrero, and Haro 2005). Therefore it is conceivable that these
specific CpGs within their context could potentially be involved in regulation of CPT1A
gene expression.
Lastly, we compared the regression results directly for cg00574958, which is the
most significantly associated CpG with TG levels. Plotting of TG levels versus DNA
methylation levels at this CpG showed an inverse correlation(figure 3.5). These data
suggest that high fasting TG levels were associated with low methylation across
individuals in CD4+ T cells. The main effect of fasting should upregulate beta oxidation
in the liver. Therefore, the methylation effect observed in lymphocytes could be reflective
of methylation levels in the liver as a biomarker of lipid metabolism. Therefore, we
hypothesized that fasting could potentially modulate gene expression of the CPT1A gene
through an epigenetic mechanism at these isolated CpGs in the CPT1A gene.
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Fig 3.3: Epigenome-wide association Manhattan plot for TG (A) and (B)
for VLDL-C. Each color represents a separate chromosome. Red line marks
the highest threshold significance level after Bonferroni correction for multiple
testing and the blue line represents the lower level threshold significance.
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Table 1.1 Strongest P-values from epigenome-wide association results for
TG and VLDL-C.
Marker

Chr

Location

Gene

P-value

TGcg00574958

11

68607622

CPT1A

5.3*10-14

TGcg17058475

11

68607737

CPT1A

1.2*10-9

VLDL-C cg00574958

11

68607622

CPT1A

6.8*10-14

VLDL-C cg17058475

11

68607737

CPT1A

2.0*10-8

Fig 3.4: Location of significant CpGs associated with TGs and VLDL-C
within intron 1 of the CPT1A gene between two CpG islands. Star shows the
location of the 2 CpGs, and yellow highlights and vertical bars indicate the
position of the 2 CpGs.
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Fig 3.5: Linear regression demonstrated an inverse association between
baseline TG and methylation levels at the most significant CpG genomewide.
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C. RNA EXTRACTION FROM FROZEN BUFFY COATS
To test our hypothesis that CPT1A gene expression could be influenced by
methylation levels (and TG levels), we first developed a total RNA isolation procedure
from frozen buffy coats. A number of different procedures were tested for isolation of
high quality total RNA from buffy coats. First, RNA extraction was carried out using the
QIAamp RNA blood mini kit for total RNA purification, which involved pelleting of
cells and lysis of red blood cells followed by extraction of RNA from the white blood cell
pellet. A second isolation kit was used to process thawed buffy coats with the MagaZorb
total RNA mini-prep kit. This kit is a proprietary SPRI-bead based isolation of total RNA
and should yield high quality RNA, but it is designed for fresh blood samples. After
much testing, we developed a Trizol-based extraction procedure that allowed high quality
yields of total RNA that combined homogenization of buffy coats in Trizol, followed by
QIAgen RNeasy isolation of total RNA with on column DNAse digestion. The trizol
protocol proved to be better than all other RNA extraction kits from frozen buffy coats
for isolation of high quality RNA required for subsequent real time quantitative RT-PCR.
The quality of RNA (RNA integrity) was assessed using an Agilent Bioanalyzer
2100 across all isolated total RNAs. A Bioanalyzer used a microfluidic chip system to
assess fluorescence dye-incorporated nucleic acids in direct comparison to RNA size
ladder and a baseline marker that allows for autocalibration of total eukaryotic RNA
samples according to standard migration of ribosomal bands on the chip. Based on a
observed peaks within electropherograms associated with the migration of nucleic acids,
the integrity of RNA can be measured by location of ribosomal bands, their relative
quantity, and any lower molecular weight RNA degradation products. Agilent
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Bioanalyzer software allows for generation of an overall RNA integrity number (RIN)
that provides a standard for RNA quality. Typically, a RIN value above 8 is considered
very high quality RNA. All total RNAs isolated using kits that required cell pellets and
prolonged treatment of thawed samples yielded very low quality RNAs (figure 3.6 A)that
did not generate RINs due to extremely poor quality as 28S and 18s ribosomal bands
were not detectable (figure 3.6 B). However, in direct contrast, the developed Trizol
procedure yielded very high resolution ribosomal bands that yielded high quality total
RNA with RIN values that were within an acceptable range for quantitative RT-PCR
(figure 3.7). The mean RIN value was 9 across all isolated samples. We used the Trizol
extraction procedure across 95 frozen buffy coat samples.
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Fig 3.6: A) Bioanalyzer gel images. Samples 1 to 12 that were isolated with cell pellet
or magnetic bead-based total RNA isolation procedures. B) RIN values. Could not be
reliably determined due to lack of detection of ribosomal bands .

Fig 3.7: A) Bioanalyzer gel images. Total RNA extracted using the developed Trizolbased procedure and (B) RIN values. Across 87 isolated total RNA samples using this
procedure .
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D. CPT1A GENE EXPRESSION ANALYSIS
Total RNA samples from buffy coat from 87 GOLDN individuals that passed our
assessment of RNA quality by Bioanalysis were used for cDNA synthesis. For
development of quantitative RT-PCR determination of CPT1A expression levels, we
selected inventoried TaqMan primer/probe sets available at Life Technologies. All probes
used FAM fluorescence. We selected 2 separate probe sets designed against the 5’ end
(spanning exons 2 and 3) and within the middle of CPT1A transcripts (spanning exons 11
and 12) to serve as internal validation for expression levels. Due to the inability to deplete
the red blood cells included within the buffy coat samples, we carefully selected four
internal controls that were previously analyzed using qPCR in other gene expression
studies from whole blood. The first study assessed gene expression levels across all blood
cell populations using Affymetrix expression microarrays that analyzed 33,000 genes
from 526 individuals(Forrest et al. 2005). Another study particular was done to find the
most stably expressed genes within whole blood (Stamova et al. 2009). Based on these
studies and genes that we anticipated to be expressed in lymphocytes and in red blood
cells, we selected a number of potential endogenous control TaqMan assays and
performed quantitative RT-PCR. To verify which endogenous controls were most stably
expressed across all samples, we used an Expression Suite software tools that compares
stability scores across all genes analyzed across all 384 well plates used in experiments.
All reactions were run in triplicates and any flagged individual reaction wells with poor
quality that failed quality control were removed from the analysis. In our study, we
selected probes for HBZ, DECR1, B2M, GAPDH, TFRC and PPIB as internal control
genes along with two assays for CPT1A. PPIB and DECRI were both previously reported
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to be stably expressed in a blood. Expression stability scores were relatively compared
across all endogenous controls (figure 3.8). These relative stability scores are generated
based on the accurate normalization of real-time quantitative RT-PCR data
(Vandesompele et al. 2002) . We found that GAPDH yielded the highest relative stability
score (4.0) when compared to all endogenous controls and was discarded from analysis.
HBZ was used as an internal control for minor red blood cell contribution, but was not
used in the analysis because Ct values were relatively much higher than all other genes.
Lower abundance of HBZ expression confirmed that red blood cell contribution was
lower, and suggested enrichment of the frozen sample in buffy coat layers. B2M was
used because it is enriched for expression in white blood cells, but was also discarded as
a candidate endogenous control because its relative Ct value across samples was much
lower than CPT1A targets and remaining candidate endogenous controls. For
comparison, B2M held the highest relative stability score (0.98) compared to scores for
the final selected endogenous controls PPIB (0.61), DECR1 (0.66), and TFRC (0.82) that
were used in the analysis. Using median-centered Ct values from averaged CPT1A Ct
values from the 2 separate probes that were highly correlated and showed very little
variation, averaged median-centered Ct values were subtracted from target Ct values to
generate ddCt. We then calculated relative fold levels across samples for CPT1A
expression. The selected representative individuals used to assess the gene expression
levels were unrelated which allowed for a simple linear regression model with
methylation and fold expression. A negative correlation was observed between
methylation levels at the most significant CpG within CPT1A (cg00574958) and fold
level expression values (figure 3.9). The data suggested that lower methylation levels
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corresponded with higher expression levels. This result is typical for CpGs that may be
involved in regulation of gene expression positioned in CpG islands(or in this case very
close).
To strengthen our confidence in the methylation levels observed by
methylation450 arrays, we also used a targeted capture sequencing procedure to bisulfite
sequence the CPT1A gene region from approximately 121 participants. Analysis of
methylation levels at cg00574958 exhibited a very strong correlation between percent
methylation levels across all individuals (r=0.83 and P=5.4*10-31)(figure 3.10). Therefore
the bisulfite sequencing on the CPT1A gene confirmed the methylation450 array data.
Overall, we found that meth%ylation levels at cg00574958 are both inversely
proportional to TG levels and to CPT1A fold expression values.
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Fig 3.8: The Ct values of all genes across the 87 samples used for assessment of
CPT1A fold level expression.
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Fig 3.9: Inverse relationship between CPT1A expression levels and
percent methylation at cg00574958 positioned within intron 1 of the
CPT1A gene.
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Fig 3.10: Percent Methylation (Cross-Disorder Group of the
Psychiatric Genomics et al.) values at cg00574958 from
methylation450 arrays and by bisulfite sequencing. Strong correlation
between these values demonstrate the cross validation reliability of the
methylation levels determined by sequencing and methyl450 array
platforms.

!

%(!

!

CHAPTER 4
DISCUSSION

A. ISOLATION OF CD4+ T CELLS
In this current study, we extracted DNA from Dynabead-sorted CD4+ cells from
thawed buffy coats. DNA extraction from thawed samples was examined in direct
comparison with sorted CD4+ T cells from freshly isolated buffy coats as controls. There
were few isolated GOLDN samples that clustered with buffy coat controls while they
clustered closer to freshly isolated T cells and indicates that the level of enrichment of
cells from thawed samples was comparable to fresh samples. However, there was some
technical variation among these cell isolations and this was corrected with the linear
models used to test for genome-wide significance of methylation with TG levels by using
principle components within the analysis. Furthermore, use of CD4+ T cells reduces the
complexity of the studied tissue and focuses the epigenetic effect on a single cell type.
Previous studies in the Absher Lab have shown that whole blood samples reflect
methylation changes within multiple blood cell types that may provide a signature of
cellular changes within a tissue, but also may confound genome wide association results
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(Adalsteinsson et al. 2012) (Talens et al. 2010). Overall these results indicate that
enrichment of cell populations from slowly thawed buffy coat samples is feasible with
gentle sorting procedures with Dynabeads.

B. IDENTIFICATION OF CPGs ASSOCIATED WITH TRIGLYCERIDE
LEVELS
The Illumina Infinium Human Methylation450 Beadchip was use to find DNA
methylation associated with fasting blood lipids. After quality control of array results,
approximately 461,000 CpG sites were evaluated for association with TG, LDL-C, HDLC, VLDL-C and TC in 995 individuals from GOLDN study. Nine genes met significance
criteria after correction for age, sex, and study site. CPT1A was isolated as an important
epigenetic signature for fasting TG and VLDL-C within T lymphocytes. CPT1A provides
a key enzymatic step required for the transport of TGs across the inner mitochondrial
membrane for beta-oxidation. Therefore, the association of TG levels with a CpG
methylation near CPT1A directly implicates CPT1A in as a gene that could be potentially
regulated by an epigenetic mechanism in response to dietary fat. In previous candidate
gene association studies, a sequence variant in CPT1A associated was associated with
fatty acid desaturase activity in an Eskimo population (Voruganti et al. 2012). Another
study done on Eskimo individuals showed the P479L variant in CPT1A was associated
with HDL-cholesterol an obesity phenotypes (Lemas et al. 2012). Furthermore, it was
also suggested that indices of obesity are modulated by an interaction between CPT1A
variants and fat intake. Other previous studies have shown the association of sequence
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variants within CPT1A with lipid and other cardiovascular phenotypes. A GWAS study
showed that the top 25 SNPs that are linked with triglyceride levels explained the
observed variance by nearly 10- 20% (Saxena et al. 2012). Our result showed that
cg00574958 within the intron 1 of CPT1A showed a strong relationship with triglyceride
levels and based on 995 individuals, this CpG alone explained observed variance by
nearly 10%. These data strongly implicate epigenetic mechanisms in response to TG
levels that could possibly better explain observed variance for TGs than sequence
variations themselves. Our study of 995 individuals from the GOLDN study showed the
first evidence of epigenetic variation in CPT1A that is associated with TG and other lipid
traits. DNA methylation showed inverse association with TG level at cg00574958 in
CPT1A.

C. EPIGENETIC REGULATION OF CPT1A GENE EXPRESSION
Total RNA was extracted from 87 samples from individuals that were also
analyzed for DNA methylation levels. We tested the correlation between DNA
methylation and expression of CPT1A. Clearly we found that the extraction of total RNA
from frozen samples was extremely difficult using various commercially available kits
and without the Trizol method, high quality RNA was not accessible. RNA extracted
with the Trizol protocol proved to be the ideal method for extraction. By qPCR, we
showed that the relative gene expression levels were inversely correlated with percent
methylation at cg00574958. A pervious study done in a CPT1A knockout mouse model
suggested deletion of CPT1A expression resulted in increase levels of triglycerides in the
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liver that resembled carnitine palmitoyltransferase deficiency (van der Leij, Drijfholt, and
Kuipers 1999, Dobbins et al. 2001). This deficiency is an autosomal recessive disorder of
fatty acid oxidation due to inability to transport long chain fatty acids into the
mitochondria and results in hypoketotic hypoglycemia that occurs after fasting. This
disease is usually detected in infancy or in early childhood (Bougneres et al. 1981).
Our results suggest that epigenetic changes in association with TGs within T lymphocytes
could reflect a signature that may also be found in liver, but our study has not analyzed
liver tissue or hepatocytes. Furthermore, with the increase in CPT1A gene specific
methylation associated with lower fasting TG levels and lower concordant CPT1A gene
expression, T cells may serve as a proxy indicator of lipid levels. While we cannot be
certain that the same potential mechanism takes place in the liver, the high level of TGs
may have effect on methylation. Indeed fasting usually leads to the upregulation of
CPT1A gene expression through PPARalpha dependent signaling in liver tissue. CPT1A
is expressed in T lymphocytes, but our expression studies were done using whole buffy
coat. It is likely that the lower fold level values could potentially indicate that the CPT1A
expression levels could be specifically affected in CD4+ cell populations. While we
cannot be certain about the order of events in a potential mechanism, high TG may cause
the decrease in methylation that leads to high expression of CPT1A (Figure 6.1).
Alternatively, lower methylation may permit upregulation of CPT1A expression that
allows for increased fasting TG levels that varies across individuals. Whatever the case,
the relationship seems consistent between fasting TG levels, and CPT1A gene expression
with decreased methylation as fasting typically raises CPT1A gene expression through
PPAR-dependent signaling in order to increase free fatty acids available for an energy
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source(Napal, Marrero, and Haro 2005). PPARa is a direct target of fenofibrate, a drug
that is used to treat individuals with high TGs (Harano et al. 2006). Fenofibrate
effectively lower TG levels by upregulating genes involved in lipid metabolism. Lastly,
TG levels are also connected to homocysteine levels that may influence the SAM
biochemical pathway for generation of methyl donor availability for DNA methylation,
but our results suggest very specific methylation events that would not be produced by
general or global changes in methylation. Overall, the exact mechanism that could be
reflected in these results remains to be determined.
We recently found in ENCODE data that the DNA methylation level in the liver
at the CpGs we have isolated is different from lymphocyte-based cell lines. This makes it
possible that the percent methylation and gene expression levels in lymphocytes may
alternatively not reflect methylation and gene expression in liver tissue. Future work is
needed to see the effect of gene expression and percent methylation in liver through the
use of animal models or cell culture studies. We also have collected 3.5h samples after a
high fat shake intake and at 3 weeks followup after fenofibrate treatment that was
initiated following the 3.5h collection. CPT1A gene expression and methylation levels
can be assessed at these other time points to understand the relationship between
fenofibrate activity and epigenetic alterations to the CPT1A gene. Interestingly, we found
2 reported PPARalpha binding sites upstream adjacent to the lipid-sensitive CpGs that are
within an imported VISTA enhancer region linked to the upstream CpG island.
Furthermore, there is also a highly conserved mammalian region downstream that has not
been investigated. We hypothesize that T cells could be used to assess fenofibrate
intervention on DNA methylation and regulation of T-cell specific expression of CPT1A.
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This enhancer site could somehow be influenced by nearby DNA methylation events.
Interestingly, all of the highly significant CpGs associated with cholesterol and TGs are
located within intronic regions. We are uncertain of whether this is a specific result
whereby there is a shared motif among these intronic regions or whether this result is
produced by chance based on basic global coverage of CpGs within or near intronic CpG
islands that are overrepresented across the methylation450 array.
In summary, our results indicated that CPT1A expression could be increased due
to decreased methylation when there is a high level of serum TGs. This model requires
further work to support the hypothesis; we need to understand the mechanism that
changes triglyceride level regulated by CPT1A gene. While our results show the
correlation between the DNA methylation and CPT1A expression in lymphocytes, it
remains to be seen if the same result would be generated in liver tissue. As CP1TA is a
key enzyme in beta oxidation and a marker of lipid metabolism, it is necessary to uncover
the mechanism for gene regulation in liver compared to lymphocytes, and whether there
is truly a function for CPT1A in T cells. Our finding nonetheless provides a novel
approach to assessment of epigenetic variation within CPT1A that may help to
understand how lipid metabolism varies among individuals.
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